Tarapur-based manufacturer of Active Pharmaceutical Ingredients (bulk drugs) — erythromycin/macrolide salts, anti-TB, anti-malarial and corticosteroid APIs — for regulated export markets
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 13 | 25 | 25 | 25 | 25 | 25 | 50 | 50 |
| Reserves | 150 | 166 | 189 | 216 | 266 | 301 | 277 | 302 |
| Borrowings | 45 | 14 | 4 | 1 | 3 | 11 | 0 | 0 |
| Other Liabilities | 119 | 128 | 129 | 163 | 152 | 170 | 182 | 205 |
| Total Liabilities | 326 | 333 | 347 | 405 | 446 | 507 | 509 | 557 |
| AssetsFixed Assets | 84 | 71 | 61 | 53 | 49 | 58 | 61 | 57 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Investments | 80 | 31 | 43 | 91 | 97 | 106 | 71 | 84 |
| Other Assets | 163 | 230 | 243 | 261 | 300 | 342 | 376 | 416 |
| Total Assets | 326 | 333 | 347 | 405 | 446 | 507 | 509 | 557 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 |
| Cash from Investing | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 |
| Cash from Financing | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -22 | 13 | -25 | 27 | 52 | 8 | 17 | -11 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (22.5×) and current (18.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 4.2% growth and a 19× exit, ₹78 only delivers your return if you pay ₹40. The price is currently baking in 17% growth.
EPS grows 4.2%/yr for 5 years, then fades to 6% over 2, exits at 19×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 4.2% | 4.27 |
| FY28 | 4.2% | 4.45 |
| FY29 | 4.2% | 4.64 |
| FY30 | 4.2% | 4.83 |
| FY31 | 4.2% | 5.04 |
| FY32 | 5.1% ·fade | 5.29 |
| FY33 | 6.0% ·fade | 5.61 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.